Vancomycin use in pediatric hematology-oncology patients.
Across-sectional study was performed of pediatric hematology-oncology patients who received vancomycin; use was compared to the Centers for Disease Control and Prevention (CDC) recommendations for vancomycin use. Thirty-seven patients received 308 doses of vancomycin. AR patients initially received vancomycin as empirical therapy; 100% of this use was not consistent with the CDC recommendations.
Hopkins
H A
HA
Hospital Infections Program, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, Georgia 30333, USA.
Sinkowitz-Cochran
R L
RL
Rudin
B A
BA
Keyserling
H L
HL
Jarvis
W R
WR
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D017723:Drug Utilization Review; D005260:Female; D005845:Georgia; D019983:Guideline Adherence; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D017053:Infection Control / Q000592:standards; D008297:Male; D016522:Oncology Service, Hospital / Q000592:standards*; D017410:Practice Guidelines as Topic; D014640:Vancomycin / Q000627:therapeutic use*; D020713:Vancomycin Resistance
D014640:Vancomycin